
DESTINY-Gastric04 Trial of T-DXd Shows OS Benefit in HER2+ Gastric Cancer
Arturo Loaiza-Bonilla, MD, MSEd, systemwide chief of hematology and oncology at St. Lukes University Health Network and co-founder and chief medical officer at Massive Bio, explains the background and findings of the phase 3 DESTINY-Gastric04 trial ( …